امازون
14-11-2003, Fri 7:06 AM
آخر سعر 0.65 وهو اعلى سعر في السنة
التداول ليوم امس 313,088 معدل التداول 36,135
التداول ارتفع بشكل ملحوظ في اخر شهرين
الشركة صغيرة ولا تتعدى قيمتها السوقية 12.2 مليون على سعر اغلاق امس
Shares Outstanding: 19.05M
شي شدني في بيانات الشركة:
Held by Insiders: 45.42%
Held by Institutions: 9.52%
وهذي تعتبر نسبة كبيرة
مجال الشركة:
Pharsight Corp. develops and markets integrated products and services that help pharmaceutical and biotechnology companies improve the drug development process
آخر نتائجها المالية:
financial results for its second quarter of fiscal year 2004 ended September 30, 2003. For the second quarter, revenue was $4.0 million, an increase of 21 percent compared with revenue of $3.3 million in the second quarter of fiscal year 2003. The net loss per share attributable to common stockholders improved to $0.05 in the second quarter, compared with a net loss per share attributable to common stockholders of $0.17 for the same period in the prior fiscal year
الشركة تخضع حالياا لاعادة هيكلة ونتائجها في تحسن ملحوظ
اهم زبائنها:
Pharsight continued to expand its relationship with Pfizer, Inc. During the second quarter, Pharsight signed agreements with Pfizer for additional consulting services, including an agreement with Pfizer Limited in the United Kingdom where Pharsight will extend its consulting services through the next year at that location.
In addition to expanding current relationships, Pharsight added new customers to its growing roster. During the second quarter of fiscal year 2004, Pharsight signed consulting service agreements with three new customers, Angiogenix, Inc., Biogen, Inc. and IDEC Pharmaceuticals.
الشركة مؤخرا احتلت المركز 186 ضمن اسرع 500شركة تكنلوجيا نموا في امريكا الشمالية من الفترة من1998 الى 2002
التداول ليوم امس 313,088 معدل التداول 36,135
التداول ارتفع بشكل ملحوظ في اخر شهرين
الشركة صغيرة ولا تتعدى قيمتها السوقية 12.2 مليون على سعر اغلاق امس
Shares Outstanding: 19.05M
شي شدني في بيانات الشركة:
Held by Insiders: 45.42%
Held by Institutions: 9.52%
وهذي تعتبر نسبة كبيرة
مجال الشركة:
Pharsight Corp. develops and markets integrated products and services that help pharmaceutical and biotechnology companies improve the drug development process
آخر نتائجها المالية:
financial results for its second quarter of fiscal year 2004 ended September 30, 2003. For the second quarter, revenue was $4.0 million, an increase of 21 percent compared with revenue of $3.3 million in the second quarter of fiscal year 2003. The net loss per share attributable to common stockholders improved to $0.05 in the second quarter, compared with a net loss per share attributable to common stockholders of $0.17 for the same period in the prior fiscal year
الشركة تخضع حالياا لاعادة هيكلة ونتائجها في تحسن ملحوظ
اهم زبائنها:
Pharsight continued to expand its relationship with Pfizer, Inc. During the second quarter, Pharsight signed agreements with Pfizer for additional consulting services, including an agreement with Pfizer Limited in the United Kingdom where Pharsight will extend its consulting services through the next year at that location.
In addition to expanding current relationships, Pharsight added new customers to its growing roster. During the second quarter of fiscal year 2004, Pharsight signed consulting service agreements with three new customers, Angiogenix, Inc., Biogen, Inc. and IDEC Pharmaceuticals.
الشركة مؤخرا احتلت المركز 186 ضمن اسرع 500شركة تكنلوجيا نموا في امريكا الشمالية من الفترة من1998 الى 2002